HLB BioStep and its subsidiary HLB BioCode recently announced the signing of a Memorandum of Understanding (MOU) with CLIPS BnC, a Contract Research Organization (CRO). The agreement, revealed on Tuesday, aims to establish a seamless collaboration system bridging preclinical and clinical stages.
The cornerstone of this partnership lies in combining HLB BioStep and HLB BioCode’s preclinical evaluation and analysis capabilities with CLIPS BnC’s expertise in clinical trial design and development strategies. This synergy is expected to create an integrated development environment that smoothly connects preclinical and clinical processes.
Under this collaboration, HLB BioStep and HLB BioCode will conduct thorough preclinical evaluations to assess the viability of entering clinical trials. Meanwhile, CLIPS BnC will proactively incorporate the latest regulatory guidelines required at the clinical stage into the preclinical design phase.
This strategic approach aims to minimize trial and error during the development process while enhancing the completeness and reliability of data.
The partnership will enable the three companies to support their clients in developing consistent strategies throughout the entire drug development process, from preclinical to clinical stages.
To achieve this goal, they plan to establish an integrated collaboration system that seamlessly connects early development phases with clinical stages. The companies will also actively pursue joint contracts and development collaborations across both preclinical and clinical domains.
It’s worth noting that this agreement represents more than just a technical collaboration; it signifies a strategic partnership based on capital trust. In January, HLB BioStep demonstrated its commitment by participating in CLIPS BnC’s third-party capital increase, securing equity in the company.
Baek Seong-jin, Chief Executive Officer (CEO) of HLB BioStep, expressed enthusiasm about the agreement, stating that this partnership marks the beginning of a collaboration that unifies preclinical and clinical processes into a single, cohesive system. Its three companies will immediately launch joint sales efforts, focusing on high-demand projects to generate tangible contracts and sales results in the short term.